Polaryx Therapeutics Appoints New Chief Medical Officer

What Happened
Polaryx Therapeutics, Inc. filed a Form 8-K reporting the appointment of Will Charlton, M.D., M.A.S., as Chief Medical Officer, effective September 1, 2026. The company announced the appointment on September 1, 2026 after making the decision on August 27, 2026.

Key Details

• Appointment: Will Charlton, M.D., M.A.S., named Chief Medical Officer, effective September 1, 2026.
• Announcement and filing dates: Company decision dated August 27, 2026; press release and 8-K disclosure dated September 1, 2026.
• Background: Board-certified pediatric endocrinologist with 10+ years in clinical practice.
• Prior roles: SVP Clinical Development, Skeletal Dysplasia at Tyra Biosciences (Mar 2025–Jun 2026); Chief Medical Officer at Spruce Biosciences (Mar 2022–Jan 2025); VP, Clinical Development at 89bio (Nov 2020–Mar 2022). Experience includes leading Phase 2 rare disease trials and registrational-stage studies.

Why It Matters
This is a senior clinical leadership hire focused on Polaryx’s development programs in endocrinology, rare and metabolic diseases. Dr. Charlton’s experience running Phase 2 and registrational clinical programs may impact trial design and execution going forward. The 8-K does not disclose other material terms (e.g., compensation) or operational changes beyond the appointment.